HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era

European Journal of Neurology

Volumn 18, Issue 3, 2011, Pages 527-534

  Garvey, Lucy ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cohort study; Epidemiology; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POISSON DISTRIBUTION; PRIORITY JOURNAL; SURVIVAL; TOXOPLASMOSIS;

AIDS DEMENTIA COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MENINGITIS, CRYPTOCOCCAL; TOXOPLASMOSIS, CEREBRAL;

EID: 79951662003     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03291.x     Document Type: Article

References (21)

1. Anders K, Steinsapir KD, Iverson DJ, et al. Neuropathologic findings in the acquired immunodeficiency syndrome (AIDS). Clin Neuropathol 1986; 5: 1-20.
2. Mocroft AJ, Lundgren JD, d'Armino Monforte A, et al. Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol 1997; 26: 400-407.
3. Fong IW, Toma E. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Clin Infect Dis 1995; 20: 1305-1310.
4. Bacellar H, Muñoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS Cohort Study, 1985-1992. Neurology 1994; 44: 1892-1900.
5. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56: 257-260.
6. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320-328.
7. Ledergerber B, Egger M, Telenti A. AIDS-Related opportunistic illness and potent antiretroviral therapy. JAMA 2000; 283: 2653-2654.
8. Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001; 33: 1747-1755.
9. Tassie JM, Gasnault J, Bentata M, et al. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS. 1999; 13: 1881-1887.
10. Grabar S, Lanoy E, Allavena C, et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9: 246-256.
11. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care. 2009; 21: 284-293.
12. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005; 11: 265-273.
13. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63: 822-827.
14. UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5: 115-124.
15. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48: 1138-1151.
16. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72: 1458-1464.
17. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006; 67: 383-388.
18. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007; 45: 174-182.
19. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-439.
20. Thiyagarajan A, Garvey LJ, Pflugrad H, et al. Cerebral function testing differs in HIV-infected subjects with and without chronic HCV co-infection. Clin Microbiol Infect. 2010; 16: 1579-1584 ( in press, early view date April 2010).
21. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171-177.